85.73 0.00 (0.00%)
After hours: 6:04PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.52 - 86.56|
|52 Week Range||64.18 - 89.09|
|PE Ratio (TTM)||37.10|
|Forward Dividend & Yield||2.08 (2.42%)|
|1y Target Est||N/A|
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16.
In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million (45 million euros).
U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ...
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
In September, the FDA approved Eli Lilly's (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+.
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.